Rexahn Pharmaceuticals has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology to develop RX-0201 (Archexin) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
CVC Capital Partners has launched a new specialty pharmaceutical company in the UK following the completion of its $703m acquisition of a part of Israel-based Teva Pharmaceutical Industries’ global women’s health business.
Seattle Genetics has agreed to acquire Cascadian Therapeutics, a clinical-stage biopharmaceutical company engaged in the development of product candidates for the treatment of cancer, for around $614m.
Clinical-stage biotech company BridgeBio Pharma has licensed infigratinib (BGJ398), a selective inhibitor of the tyrosine kinase receptor FGFR and a late-stage oncology drug, from Novartis.
Innate Pharma has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.
French drugmaker Sanofi has agreed to acquire Ablynx, a Belgian biopharma company focused in the discovery and development of Nanobodies, for about €3.9bn.
Spectris has completed the acquisition of Concept Life Sciences Group of companies from Equistone Partners and company management for £163m.
Avacta Group has signed a licensing agreement with Glythera for its Affimer technology after a successful proof-of-concept study.
UK-based Vaccitech, which is developing a universal influenza vaccine and other vaccine-related products, has bagged £20m ($27.1m) of funding from various investors.
Mallinckrodt has agreed to divest several hemostasis products to Baxter International for about $185m, with upfront payment of $153m, inclusive of existing inventory, and the remainder in potential future milestones
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.